All News
Rituximab Efficacy in Systemic Sclerosis
The DESIRES trial studied rituximab (RTX) in patients with systemic sclerosis (SSc) and showed clinically significant improvement in skin and lung outcomes after a subsequent 24-week open-label extension phase.
https://t.co/cqlVo104Y9 https://t.co/dYgBsj65BJ
Links:
Dr. John Cush RheumNow ( View Tweet)
Nailfold Capillaroscopy doesnt have to be expensive: use handheld Carson Microbrite (~$10) 10x or 20 x handheld microscope (w/ KY gel) to evaluate #Raynauds #scleroderma https://t.co/aJ6K6JeVCp https://t.co/0aUBnqxhic https://t.co/54s66sWvyv #RWCS2022
#BestOf2022
Links:
Dr. John Cush RheumNow ( View Tweet)
Nailfold Capillaroscopy doesnt have to be expensive: use handheld Carson Microbrite (~$10) 10x or 20 x handheld microscope (w/ KY gel) to evaluate #Raynauds #scleroderma https://t.co/aJ6K6JeVCp https://t.co/0aUBnqxhic https://t.co/54s66sWvyv #RWCS2022
#BestOf2022
Links:
Dr. John Cush RheumNow ( View Tweet)
Nailfold Capillaroscopy doesnt have to be expensive: use handheld Carson Microbrite (~$10) 10x or 20 x handheld microscope (w/ KY gel) to evaluate #Raynauds #scleroderma https://t.co/aJ6K6JeVCp https://t.co/0aUBnqxhic https://t.co/54s66sWvyv #RWCS2022
#BestOf2022
Links:
Dr. John Cush RheumNow ( View Tweet)
JAK Inhibitor Potential in Systemic Sclerosis-Associated ILD
The occurrence of interstitial lung disease (ILD) in Systemic sclerosis portends serious morbid and mortal outcomes for those affected. This review examines the available clinical literature on the potential benefits and outcomes of JAK inhibitor use in SSc=ILD.
Read Article
3388 pts in J Hopkins Scleroderma study found 29% w/ calcinosis (13.5% these w/ heavy burden calcinosis/HBC). Calcinosis assoc w/ diffuse SSc, disease severity (PH, ILD, CVD, GI, renal crisis, myopathy)(OR 2.9- 6.9) & PM/Scl Abs (OR 17.31) https://t.co/VsRDg5Utik https://t.co/AMqHUveJ6e
Links:
Dr. John Cush RheumNow ( View Tweet)
3388 pts in J Hopkins Scleroderma study found 29% w/ calcinosis (13.5% these w/ heavy burden calcinosis/HBC). Calcinosis assoc w/ diffuse SSc, disease severity (PH, ILD, CVD, GI, renal crisis, myopathy)(OR 2.9- 6.9) & PM/Scl Abs (OR 17.31) https://t.co/ksdPcH9W0O https://t.co/OvI9wytf5H
Links:
Dr. John Cush RheumNow ( View Tweet)
Comparison of 227 Systemic Sclerosis pts w/ & without ILD shows SSc-ILD to have more muscle Dz [OR 2.55], LVDD [OR 2.36], PAH [OR 9.13], dcSSc [OR 2.86], PLR [OR 1.005], elevated KL-6 [OR 2.03], and anti-Scl-70 [OR 3.1]. https://t.co/Pzx9N5rPcF https://t.co/F8mBQ1u5iL
Links:
Dr. John Cush RheumNow ( View Tweet)
#ACR22 Highlights. ILD in CTDs #rituximab = #cyclophoshamide at 6 mo for CTD ILD & ritux better on skin score in #scleroderma RECITAL RCT abst0003 but #pirfenidone added to #MMF not better than MMF alone in SLSIII RCT—ILD w #SSc abst#520 vs in SENCIS #nintedanib is + @RheumNow
Janet Pope Janetbirdope ( View Tweet)
☝️Treatment is the 3rd reason why we need to order a BL HRCT in pts with ILD; "We can't treat SSc-ILD if we are not able to detect SSc-ILD" - Dr. Elana Bernstein
#ACR @RheumNow #rheumatology https://t.co/ooZVSbt3Xf
sheila RHEUMarampa ( View Tweet)
Ab1672 #ACR22 SSc on Women's Health
100 pts - 75% lSSc
59% sexuality aff by SSc (vag dryness 67%, dig ulcers 37%, GI 37%, dyspnea 20%)
48 pts dx during repro ys - 73% never discuss contraception, 30% didn't reach family plan
22 pt - 43 pregn, 33 birth: C-sxn, low bth wt
@Rheumnow https://t.co/JRkyCVEXLB
Eric Dein ericdeinmd ( View Tweet)
Mihai et al. Immunosuppressive treatment in SSc assoc lower GI symptom score. @RheumNow #ACR22 Abstr#2174 https://t.co/Y1gyRe8ron https://t.co/tz9cIESzqo
Richard Conway RichardPAConway ( View Tweet)
Quinlivan et al. GORD in SSc. Common - 94%. GORD treatment assoc improved survival HR 0.58. No assoc with ILD development/severity/progression but GORD treatment assoc improved survival in ILD HR 0.5. If PPI+H2 HR 0.33 . @RheumNow #ACR22 Abstr#2159 https://t.co/zk718ziFGJ https://t.co/WctfOr9qyf
Richard Conway RichardPAConway ( View Tweet)
DAVIX is a promising surrogate outcome measure of vascular disease in SSc. Questions around cost and access remain. Abs 1541 #ACR22 @RheumNow https://t.co/KJgtcG5ah8 https://t.co/NsK7b8fQFt
Dr. Rachel Tate uptoTate ( View Tweet)
@RheumNow interview with Dr. Lauren Smith on race differences in MMF responses in systemic sclerosis at #ACR22
@jhrheumatology @JHRheumFellows
https://t.co/aSRHiJoIkE
Eric Dein ericdeinmd ( View Tweet)
Goldman et al. RTX, TCZ in SSc ILD. 129 patients, 87 RTX, 32 TCZ, 10 both. Median changes in %FVC and %DLCO pre-and post-treatment were +0.35% and -0.8% for rituximab and -0.9% and +0.2% for tocilizumab. Majority stable/improved @RheumNow #ACR22 Abstr#1520 https://t.co/ydY5FGEYnQ https://t.co/O9QD7nkjdZ
Richard Conway RichardPAConway ( View Tweet)
Hoffmann-Vold et al. SSc ILD frequently progresses even in long-standing SSc. Not just a disease of early SSc! @RheumNow #ACR22 Abstr#1536 https://t.co/nKiY2xFxfk https://t.co/W7SDm6QFpQ
Richard Conway RichardPAConway ( View Tweet)
Makol @AshimaMakol et al. Multimorbidity in SSc . SSc higher burden multimorbidity at diagnosis and higher risk of developing multimorbidity over time @RheumNow #ACR22 Abstr#1190 https://t.co/VopFI6U5G5 https://t.co/hKKPC7v8EN
Richard Conway RichardPAConway ( View Tweet)
Herrán et al. Anti-vinculin abs in SSc. Single centre. Seen in 25%. Slow gastric transit (37% vs 21%). More LcSSc (OR 5), more thyroid disease (OR 3.2), less lung (OR 0.19). @RheumNow #ACR22 Abstr#1068 https://t.co/kPVgWPUl00 https://t.co/kmTERf78Ae
Richard Conway RichardPAConway ( View Tweet)
Ramahi @sclerodermaUM et al Risk factors for ILD decline in SSc. Anti-Topoisomerase I only identified factor in multivariable model. @RheumNow #ACR22 Abstr#1524 https://t.co/lc2BPjgqiC https://t.co/qx3M6dfd3w
Richard Conway RichardPAConway ( View Tweet)